Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Macdougall IC - C.E.R.A. is unquestionably the longest-acting agent based on pharmacokinetic data, and evidence for the efficacy of once -monthly C.E.R.A. is accumulating. Although all ESAs correct anaemia and maintain haemoglobin in the majority of CKD patients, it is likely that not all ESAs are the same with regard to their optimum dosing frequency.

Related Articles

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study
Hemodialysis International, 11/05/09    Relevance Score: 91%

Today in Endocrinology...keeping you current

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Urologic Oncology: Seminars and Original Investigations, 12/03/09

Response of Secondary Hyperparathyroidism to Cinacalcet Depends on Parathyroid Size
Nephron: Clinical Practice, 12/01/09

Stone composition and metabolic status
Urological Research - Urolithiasis, 11/25/09

Today in Pharmacology/kinetics...keeping you current

Medium-size-vessel vasculitis
Pediatric Nephrology, 12/04/09

Sirolimus and Cyclosporine A Alter Barrier Function In Renal Proximal Tubular Cells through Stimulation of ERK 1/2 Signaling and Claudin-1 Expression
American Journal of Physiology: Renal Physiology, 12/04/09

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Urologic Oncology: Seminars and Original Investigations, 12/03/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address